AMS Capital’s ResMed RMD Stock Holding History

AMS Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,000	Closed	-$1.97M	–	43
2018 Q1	$1.97M	Buy	+20,000	New	+$1.89M	1.76%	15

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AMS Capital's RMD Position: Q2 2018 in Review

AMS Capital sold out of ResMed (RMD) in Q2 2018, closing a stake of 20,000 shares — an estimated $1.97M sold.

AMS Capital first reported a position in RMD in Q1 2018 and held it in 1 quarter. The position peaked at $1.97M in Q1 2018. 465 funds tracked by Wall St. Rank hold RMD as of Q2 2018.

AMS Capital reported no remaining ResMed position as of Q2 2018 after selling out during the quarter.
AMS Capital sold 20,000 ResMed shares in Q2 2018, an estimated $1.97M.
AMS Capital first reported a position in ResMed in Q1 2018 and held it in 1 quarter.
AMS Capital's ResMed position peaked at $1.97M in Q1 2018.
465 funds tracked by Wall St. Rank held ResMed as of Q2 2018.

Based on AMS Capital's 13F filing for Q2 2018, filed 31 Jul 2018.